search

Active clinical trials for "Lymphoma, B-Cell, Marginal Zone"

Results 81-90 of 288

AEDV Registry of Primary Cutaneous Lymphoma

LymphomaT-Cell12 more

Registry of patients with Primary Cutaneous Lymphoma seen at participating centers in Spain. The registry will identify patients with this disease and includes information about stage, diagnostic and therapeutic interventions and willingness to participate in further studies.

Recruiting2 enrollment criteria

Safety, PK, PD, and Antitumor Activity of Vecabrutinib (SNS-062) in B Lymphoid Cancers

Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma6 more

This is an open-label Phase 1b/2 study in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)or non hodgkin's lymphoma (NHL) who have failed prior standard of care therapies including a BTK inhibitor where one is approved for the indication.

Terminated11 enrollment criteria

Zandelisib (ME-401) in Subjects With Follicular Lymphoma or Marginal Zone Lymphoma After Failure...

Follicular Lymphoma (FL)Non Hodgkin Lymphoma1 more

This is the study of the PI3Kδ inhibitor Zandelisib (ME-401) in subjects with relapsed/refractory follicular lymphoma or marginal zone lymphoma after failure of at least 2 prior lines of systemic therapy

Terminated16 enrollment criteria

Acalabrutinib in Combination With R-ICE For Relapsed or Refractory Lymphoma

Diffuse Large B Cell LymphomaChronic Lymphocytic Leukemia2 more

The purpose of this study is to test a combination treatment of acalabrutunib when given together with rituximab-ifosfamide-carboplatin-etoposide (R-ICE) to evaluate if it will be able to improve durable responses and cure some patients.

Terminated55 enrollment criteria

Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection...

Adult B Acute Lymphoblastic LeukemiaChronic Lymphocytic Leukemia27 more

This phase I trial studies the side effects and best dose of ibrutinib in treating B-cell non-Hodgkin lymphoma that has returned or does not respond to treatment in patients with human immunodeficiency virus (HIV) infection. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. It is not yet known whether it is safe for patients with HIV infection to receive ibrutinib while also taking anti-HIV drugs.

Terminated48 enrollment criteria

A Phase II Study of Doxycycline in Relapsed NHL

Adult Diffuse Large B-Cell LymphomaMantle Cell Lymphoma Recurrent8 more

The purpose of this study is to determine whether doxycycline is effective in the treatment of relapsed Non Hodgkin Lymphomas (NHL).

Terminated24 enrollment criteria

Phase I Dose Escalation Study of IMMU-114 in Relapsed or Refractory NHL and CLL

Non-hodgkin's LymphomaFollicular Lymphoma4 more

IMMU-114 will be studied at different dose schedules and dose levels in order to assess the highest dose safely tolerated. IMMU-114 will be administered subcutaneously (under the skin). IMMU-114 will be given 1-2 times weekly for 3 weeks followed by one week of rest. This is considered one cycle. Treatment cycles will be repeated until toxicity or worsening of disease.

Terminated40 enrollment criteria

CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory...

B-cell Adult Acute Lymphoblastic LeukemiaB-cell Chronic Lymphocytic Leukemia25 more

This phase I trial studies the side effects and best dose of CPI-613 (6,8-bis[benzylthio]octanoic acid) when given together with bendamustine hydrochloride and rituximab in treating patients with B-cell non-Hodgkin lymphoma that has come back or has not responded to treatment. Drugs used in chemotherapy, such as 6,8-bis(benzylthio)octanoic acid and bendamustine hydrochloride, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as rituximab, may find cancer cells and help kill them. Giving 6,8-bis(benzylthio)octanoic acid with bendamustine hydrochloride and rituximab may kill more cancer cells.

Terminated30 enrollment criteria

Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell Non-Hodgkin Lymphoma...

Adult Non-Hodgkin LymphomaAdult Grade III Lymphomatoid Granulomatosis78 more

RATIONALE: Lenalidomide may stop the growth of cancer by blocking blood flow to the tumor. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Giving lenalidomide together with rituximab may be an effective treatment for B-cell non-Hodgkin lymphoma. PURPOSE: This phase I/II trial is studying the side effects and best dose of lenalidomide when given together with rituximab as maintenance therapy in treating patients with B-cell non-Hodgkin lymphoma.

Terminated35 enrollment criteria

Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating Patients With...

Adult Acute Lymphoblastic Leukemia in RemissionAdult Grade III Lymphomatoid Granulomatosis32 more

This clinical trial studies etoposide, filgrastim and plerixafor in improving stem cell mobilization in patients with non-Hodgkin lymphoma. Giving colony-stimulating factors, such as filgrastim, and plerixafor and etoposide together helps stem cells move from the patient's bone marrow to the blood so they can be collected and stored.

Terminated20 enrollment criteria
1...8910...29

Need Help? Contact our team!


We'll reach out to this number within 24 hrs